hero image
Dr. Daniela Bota - UC Irvine. Orange, CA, US

Dr. Daniela Bota Dr. Daniela Bota

Associate Dean of Clinical Research and Associate Professor of Neurology | UC Irvine

Orange, CA, UNITED STATES

Dr. Daniela A. Bota is a UCI Health neuro-oncologist who specializes in the treatment of primary and metastatic brain tumors.

Media

Publications:

Documents:

Photos:

loading image loading image

Videos:

Daniela Bota Intro - Hope vs. Hype: Anatomy of a Clinical Trial Daniela Bota Intro - Treating the Cancer Treatment? Radiation Biology and Stem Cells Dr. Bota on Marizomib in Patients with Glioma

Audio:

Biography

Dr. Daniela A. Bota is a UCI Health neuro-oncologist who specializes in the treatment of primary and metastatic brain and spinal cord tumors, as well as in the neurological complications of cancers.

Bota is co-director of the UCI Health Comprehensive Brain Tumor Program and is a lead investigator on several clinical trials, including novel treatments using brain tumor vaccines and the use of electrical fields to inhibit the growth of gliomas.

Areas of Expertise (5)

Clinical Trials

Neuro-Oncology

Brain Cancer

Neurology

Brain Tumors

Accomplishments (4)

Physicians of Excellence, Orange County Medical Association (professional)

2017-2019

Southern California Rising Star™ (professional)

2015 Neurology — SuperDoctors® edition of Los Angeles magazine

Ruth L. Kirschstein National Research Service Award (professional)

2006-2007

American Federation of Aging Research Glenn/AFAR Fellowship (professional)

2001

Education (2)

University of Southern California: PhD, Molecular Biology 2003

Carol Davila University of Medicine and Pharmacy: MD 1997

Affiliations (4)

  • American Board of Psychiatry and Neurology
  • Society of Neuro-Oncology
  • American Society of Clinical Oncology
  • American Academy of Neurology

Media Appearances (5)

Trump brags that he’s helping patients access medical ‘miracles.’ He isn’t.

The Washington Post  online

2019-11-15

The idea of letting people take a gamble like that has intuitive appeal. But almost a year and a half after the law’s enactment, scholars and reporters looking for evidence of its effectiveness have turned up only a small number of people who have used the law to obtain treatment. Matt Bellina, an amyotrophic lateral sclerosis (ALS) patient who campaigned for the law, has been receiving an experimental therapy still in clinical testing from BrainStorm, the New York-based company has confirmed. Daniela Bota, a neurologist at the University of California at Irvine, helped secure a nonapproved drug through Right to Try for a patient with aggressive brain cancer, she told STAT News (and confirmed to The Washington Post).

view more

Scientists develop a blood test to predict how long patients with the aggressive brain cancer that killed John McCain will live - and it could lead to custom treatments

Daily Mail  online

2019-10-30

Her family's frantic research brought Amanda to the UCI's Dr Daniela Bota and her 700-person clinical trial for adult patients to undergo treatment with a drug called Marizomib.

view more

Glioblastoma patient's tumor no longer measurable thanks to promising clinical trial

Fox News  online

2019-10-14

In their search for help, the Johnsons connected with UCI Health neuro-oncologist Dr. Daniela Bota, who is currently leading a clinical trial for 700 newly diagnosed glioblastoma patients.

view more

Brain Cancer Patient Is First to Get Untested Treatment Under Trump-Backed Law

Bloomberg  online

2019-01-10

A California man with a deadly form of brain cancer is receiving an experimental therapy under the so-called Right to Try law, the first publicly known use of the controversial legislation that was signed into law in May 2018 by President Donald Trump. The treatment, called Gliovac, is a vaccine crafted from the patient’s own cells and tissue taken from other patients with glioblastoma -- the same aggressive tumor that killed John McCain a year after his diagnosis. It’s being provided to the man, who has chosen to remain anonymous for now, by Epitopoietic Research Corp., or ERC, a closely-held Belgian company that is testing it in human trials.

view more

Dr. Bota on Marizomib in Patients with Glioma

OncLive  online

2018-08-08

Daniela Bota, MD, PhD, medical director, Neuro-Oncology Program, associate professor, Neurology School of Medicine, UC Irvine Health, discusses marizomib for the treatment of patients with glioma.

view more

Research Grants (1)

The Mechanisms of Chemotherapy Induced Cognitive Defects

National Institutes of Health (NIH) 

2011-2012

Articles (5)

Mitochondrial-associated impairments of temozolomide on neural stem/progenitor cells and hippocampal neurons MitochondrionF

Naomi Lomeli, Kaijun Di, Diana C Pearre, Tzu-Feng Chung, Daniela A Bota

2020 Primary brain tumor patients often experience neurological, cognitive, and depressive symptoms that profoundly affect quality of life. The DNA alkylating agent, temozolomide (TMZ), along with radiation therapy forms the standard of care for glioblastoma (GBM) – the most common and aggressive of all brain cancers. Numerous studies have reported that TMZ disrupts hippocampal neurogenesis and causes spatial learning deficits in rodents; however, the effect of TMZ on mature hippocampal neurons has not been addressed.

view more

Rindopepimut with Bevacizumab for Patients with Relapsed EGFRvIII-Expressing Glioblastoma (ReACT): Results of a Double-Blind Randomized Phase II Trial Clinical Cancer ResearchF

David A Reardon, Annick Desjardins, James J Vredenburgh, Donald M O'Rourke, David D Tran, Karen L Fink, Louis B Nabors, Gordon Li, Daniela A Bota, Rimas V Lukas, Lynn S Ashby, J Paul Duic, Maciej M Mrugala, Scott Cruickshank, Laura Vitale, Yi He, Jennifer A Green, Michael J Yellin, Christopher D Turner, Tibor Keler, Thomas A Davis, John H Sampson

2020 Purpose: Rindopepimut is a vaccine targeting the tumor-specific EGF driver mutation, EGFRvIII. The ReACT study investigated whether the addition of rindopepimut to standard bevacizumab improved outcome for patients with relapsed, EGFRvIII-positive glioblastoma.

view more

A Novel Rat Ovarian Cancer Model Developed to Examine Chemotherapy-Related Cognitive Impairments Gynecologic OncologyF

D. Pearre, N. Lomeli, D. Bota

2020 OBJECTIVES: To describe a novel method of developing an ovarian cancer intraperitoneal (IP) and subcutaneous (SC) xenograft model with the purpose of extrapolating chemotherapy-related cognitive impairments (CRCI) in tumor-bearing rats.

view more

PDCT-17 (LTBK-11). PNOC007: H3.3K27M Specific Peptide Vaccine Combined With Poly-ICLC for the Treatment of Newly Diagnosed HLA-A2+ H3.3K27M Midline Gliomas Neuro-OncologyF

Timothy Cloughesy, Kevin Petrecca, Tobias Walbert, Nicholas Butowski, Michael Salacz, James Perry, Denise Damek, Daniela Bota, Chetan Bettegowda, Jay-Jiguang Zhu, Fabio Iwamoto, Dimitris Placantonakis, Nina Martinez, J Bradley Elder, George Kaptain, David Cachia, Yaron Moshel, Steven Brem, David Picconi, Nam Tran, Do-Hyun Nam, Chul-Kee Park, Joseph Landolfi, David Tran, Rohan Ramakrishna, Karen Fink, Deborah Heros, Gelareh Zadeh, Garth Nicholas, Vivek Mehta, H Ian Robins, Clark Chen, Marshall Pitz, Jason Heth, Seema Nagpal, Michael Pearlman, Manmeet Ahluwalia, Nimish Mohile, Ryan Merrell, David Schiff, Reid Thompson, Raphael Davis, David Macdonald, Thian Kheoh, Fairooz Kabbinavar, Alexander Lossos, Michael Vogelbaum

2019 To assess within a multi-center trial the safety of H3.3K27M specific peptide vaccine in combination with poly-ICLC in HLA-A02.01+ patients diagnosed with H3.3K27M+ diffuse midline gliomas.

view more

Management of low-grade glioma: a systematic review and meta-analysis Neuro-Oncology PracticeF

Timothy J Brown, Daniela A Bota, Martin J van Den Bent, Paul D Brown, Elizabeth Maher, Dawit Aregawi, Linda M Liau, Jan C Buckner, Michael Weller, Mitchel S Berger, Michael Glantz

2018 Optimum management of low-grade gliomas remains controversial, and widespread practice variation exists. This evidence-based meta-analysis evaluates the association of extent of resection, radiation, and chemotherapy with mortality and progression-free survival at 2, 5, and 10 years in patients with low-grade glioma.

view more